Oncology, Hematology & Blood Disorders

Cancer is one of the leading causes of mortality worldwide, and the number of new cases is expected to rise. In developing countries across the Caribbean and South America, cancer remains one of the leading causes of deaths despite advances in screening and treatment options. CARIMER is committed to introducing new therapies and opportunities to patients in the region who would otherwise have to travel outside the region to be candidates for available trials. At CARIMER we have extensive experience in various classes of small molecules and biologics across a broad spectrum of cancers, including lung, breast, GI, GU, skin, leukemias, lymphomas, multiple myeloma, and MPNs.

Our in-depth experience goes even further, including:

Immunotherapies (including checkpoint inhibitors, cancer vaccines,
CAR-T cell therapies, bispecific antibodies, and cytokines)
Radiopharmaceuticals (in diagnostic and therapeutic setting)
Cancer supportive care medications (in cytopenia, nausea/vomiting, mucositis, fungal infections)
Biosimilar medicines

Our oncology experience includes:

Advanced Solid Tumors
Cervical Cancer
Chemo Induced Anorexia, Cachexia
Colorectal Cancer
Endometrial Cancer
Febrile Neutropenia
Liver Cancer
Melanoma
Myelodysplastic Syndrome

Non-Hodgkin Lymphoma
Ovarian Cancer
Prostate Cancer
Pancreatic Cancer
Renal Cell Carcinoma
Non-Small Cell Lung Cancer
Small-Cell Lung Cancer
Stomach Cancer

Core Therapeutic Areas

Rare Cancers:

Hepatocellular Carcinoma
Myelodysplastic Syndrome with Myelofibrosis
Osteosarcoma
Triple-Negative Breast Cancer

Acute Myeloid Leukemia (AML)
B-Cell Non-Hodgkin Lymphoma
Cutaneous T-Cell Lymphoma
Gastrointestinal Stromal Tumor (GIST)
Glioblastoma Multiforme (GBM)

Biosimilars in Oncology

South American and Caribbean countries often play an important role in enabling quick patient enrollment and high quality of data for trials that turn out to be particularly difficult to execute in more Western countries.

Rare Diseases

Rare disease trials come with inherent challenges arising from two elements: a sparse patient population and a wide geographical spread.

With Carimer’s position in the region, we can conduct thorough feasibility to ensure that the right sites are opened for your study which will lead to the success of your product. At Carimer, we have formed deep connections with advocacy groups for rare diseases in the region. This helps us locate hard-to-find patients. We are committed to these groups and patients who are always engaged in the clinical research space in search of a cure.

We also conduct clinical trials in diseases such as:

Hemophilia
Hemophilia B
Sickle Cell
Thrombocytopenia
Paroxysmal Nocturnal Hemoglobinuria (PNH).